{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:03Z","timestamp":1790364183826,"version":"4.1.0"},"reference-count":15,"publisher":"Chinese Center for Disease Control and Prevention","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.46234\/ccdcw2025.092","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T07:32:05Z","timestamp":1745566325000},"page":"574-579","source":"Crossref","is-referenced-by-count":3,"title":["Post-Marketing Surveillance of Adverse Events Following Recombinant Zoster Vaccine \u2014 China, 2020\u20132023"],"prefix":"10.46234","volume":"7","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minrui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zundong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25413","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Kennedy PGE, Mogensen TH. Varicella-zoster virus infection of neurons derived from neural stem cells. Viruses 2021;13(3):485. https:\/\/doi.org\/10.3390\/v13030485.","DOI":"10.3390\/v13030485"},{"key":"2","unstructured":"Expert Group on the Preparation of Consensus on the Diagnosis and Treatment of Postherpetic Neuralgia. Chinese expert consensus on the diagnosis and treatment of postherpetic neuralgia. Chin J Pain Med 2016;22(3):161-7. http:\/\/dx.doi.org\/10.3969\/j.issn.1006-9852.2016.03.001. (In Chinese)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Li Y, An ZJ, Yin DP, Liu YM, Huang ZY, Xu JF, et al. Disease burden due to herpes zoster among population aged \u226550 years old in China: a community based retrospective survey. PLoS One 2016;11(4):e0152660. https:\/\/doi.org\/10.1371\/journal.pone.0152660.","DOI":"10.1371\/journal.pone.0152660"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Sun XH, Wei Z, Lin HB, Jit M, Li ZW, Fu CX. Incidence and disease burden of herpes zoster in the population aged \u226550 years in China: data from an integrated health care network. J Infect 2021;82(2):253 \u2212 60. https:\/\/doi.org\/10.1016\/j.jinf.2020.12.013.","DOI":"10.1016\/j.jinf.2020.12.013"},{"key":"6","unstructured":"Ministry of Health of China, State Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization (AEFI). 2010. http:\/\/www.nhc.gov.cn\/jkj\/wslgf\/201402\/5dd5633d93174a7c8e93d8af7579a613.shtml. [2024-3-10]. (In Chinese)."},{"key":"7","unstructured":"Zhang LN, Li Y, Li KL, Li Y, Fan CX, Ren MR, et al. Surveillance of adverse events following immunization in China, 2021-2022. Chin J Vaccines Immun 2024;30(4):470 \u2212 84. https:\/\/doi.org\/10.19914\/j.cjvi.2024079."},{"key":"8","unstructured":"Zhang LN, Li KL, Li Y, Fan CX, Li Y, Ren MR, et al. Surveillance of adverse events following immunization in China, 2020. Chin J Vaccines Immun 2022;28(2):208 \u2212 18. https:\/\/doi.org\/10.19914\/j.cjvi.2022041."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine 2016;34(6):714 \u2212 22. https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.024.","DOI":"10.1016\/j.vaccine.2015.12.024"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, et al. Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) - United States, October 2017\u2013June 2018. MMWR Morb Mortal Wkly Rep 2019;68(4):91 \u2212 4. https:\/\/doi.org\/10.15585\/mmwr.mm6804a4.","DOI":"10.15585\/mmwr.mm6804a4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Tavares-Da-Silva F, Co MM, Dessart C, Herv\u00e9 C, L\u00f3pez-Fauqued M, Mahaux O, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine 2020;38(18):3489 \u2212 500. https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.058.","DOI":"10.1016\/j.vaccine.2019.11.058"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Colindres R, Wascotte V, Brecx A, Clarke C, Herv\u00e9 C, Kim JH, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020;16(11):2628 \u2212 33. https:\/\/doi.org\/10.1080\/21645515.2020.1741312.","DOI":"10.1080\/21645515.2020.1741312"},{"key":"13","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 2019;37(18):2482 \u2212 93. https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.043.","DOI":"10.1016\/j.vaccine.2019.03.043"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Goud R, Lufkin B, Duffy J, Whitaker B, Wong HL, Liao JM, et al. Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern Med 2021;181(12):1623 \u2212 30. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6227.","DOI":"10.1001\/jamainternmed.2021.6227"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Nelson JC, Ulloa-P\u00e9rez E, Yu O, Cook AJ, Jackson ML, Belongia EA, et al. Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. Am J Epidemiol 2023;192(2):205 \u2212 16. https:\/\/doi.org\/10.1093\/aje\/kwac170.","DOI":"10.1093\/aje\/kwac170"}],"container-title":["China CDC Weekly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/weekly.chinacdc.cn\/en\/article\/pdf\/preview\/10.46234\/ccdcw2025.092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T07:35:43Z","timestamp":1745566543000},"score":1,"resource":{"primary":{"URL":"https:\/\/weekly.chinacdc.cn\/en\/article\/doi\/10.46234\/ccdcw2025.092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46234\/ccdcw2025.092","relation":{},"ISSN":["2097-3101"],"issn-type":[{"value":"2097-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}